Novel pyridazinone derivatives as butyrylcholinesterase inhibitors

Dündar Y., Kuyrukçu Ö., Eren G., Şenol Deniz F. S., Önkol T., Erdoğan Orhan İ.

BIOORGANIC CHEMISTRY, cilt.92, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 92
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.bioorg.2019.103304
  • Dergi Adı: BIOORGANIC CHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Alzheimer's disease, Pyridazinone derivatives, Acetylcholinesterase inhibitors, Butyrylcholinesterase inhibitors, Docking, ACTIVE-SITE GORGE, MULTIFUNCTIONAL AGENTS, CRYSTAL-STRUCTURE, X-RAY, ACETYLCHOLINESTERASE, DESIGN, IDENTIFICATION, FLEXIBILITY, DISCOVERY, MODEL
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

In the current study, forty-four new [3-(2/3/4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl]methyl carbamate derivatives were synthesized and evaluated for their ability to inhibit electric eel acetylcholinesterase (EeAChE) and equine butyrylcholinesterase (eqBuChE) enzymes. According to the inhibitory activity results, [3-(2-methoxyphenyl)-6-oxopyridazin-1(6H)-yl] methyl heptylcarbamate (16c, eqBuChE, IC50, = 12.8 mu M; EeAChE, no inhibition at 100 mu M) was the most potent eqBuChE inhibitor among the synthesized compounds and was found to be a moderate inhibitor compared to donepezil (eqBuChE, IC50, = 3.25 mu M; EeAChE, IC50, = 0.11 mu M). Kinetic and molecular docking studies indicated that compounds 16c and 14c (hexylcarbamate derivative, eqBuChE, IC50, = 35 mu M; EeAChE, no inhibition at 100 mu M) were mixed-type inhibitors which accommodated within the catalytic active site (CAS) and peripheral anionic site (PAS) of hBuChE through stable hydrogen bonding and pi-pi stacking. Furthermore, it was determined that [3-(2-methoxyphenyl)-6-oxopyridazin-1(6H)-yl]methyl (4-methylphenyl)carbamate 7c (eqBuChE, IC50, = 34.5 mu M; EeAChE, 38.9% inhibition at 100 mu M) was the most active derivative against EeAChE and a competitive inhibitor binding to the CAS of hBuChE. As a result, 6-(2-methoxyphenyl)pyridazin-3(2H)-one scaffold is important for the inhibitory activity and compounds 7c, 14c and 16c might be considered as promising lead candidates for the design and development of selective BuChE inhibitors for Alzheimer's disease treatment.